Astrazeneca (AZN) EPS (Basic) (2009 - 2026)

Astrazeneca (AZN) has reported EPS (Basic) for 18 consecutive years, with $1.99 the latest figure, recorded in Q1 2026.

• In Q1 2026, EPS (Basic) fell 61.64% year-over-year to $1.99; the TTM figure through Mar 2026 stood at $7.73 (down 40.66% YoY), while the FY2025 annual figure was $6.59, up 45.25% from the prior year.
• EPS (Basic) came in at $1.99 for Q1 2026 at Astrazeneca, up from $1.79 in the prior quarter.
• The five-year high for EPS (Basic) was $5.18 in Q1 2025, with the low at -$0.48 in Q2 2022.
• Average EPS (Basic) over 5 years is $2.36, with a median of $2.3 recorded in 2023.
• The largest YoY upside for EPS (Basic) was 22690.43% in 2022 against a maximum downside of 75019828560.76% in 2022.
• Year by year, EPS (Basic) stood at $2.21 in 2022, then climbed by 4.03% to $2.3 in 2023, then slumped by 57.92% to $0.97 in 2024, then surged by 84.55% to $1.79 in 2025, then advanced by 11.33% to $1.99 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered $1.99, $1.79, and $3.32 for Q1 2026, Q4 2025, and Q3 2025 respectively.